Literature DB >> 20888739

An introduction to adaptive designs and adaptation in CNS trials.

Vladimir Dragalin1.   

Abstract

Adaptive designs learn from accumulating trial data in real time and apply this knowledge to optimize subsequent study execution. A set of design rules define a priori which modifications may be incorporated into the trial design. Judicious use of adaptive designs may increase the information value per resource unit invested by avoiding allocation of patients to non-efficacious/unsafe therapies and allowing stopping decisions to be made at the earliest possible time point. Ultimately this may accelerate the development of promising therapies.
Copyright © 2010 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20888739     DOI: 10.1016/j.euroneuro.2010.09.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  6 in total

Review 1.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  On improving human clinical trials to the level of animal ischemic stroke studies.

Authors:  Donald G Stein
Journal:  Metab Brain Dis       Date:  2014-08-30       Impact factor: 3.584

Review 3.  The ongoing pursuit of neuroprotective therapies in Parkinson disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Nat Rev Neurol       Date:  2014-12-02       Impact factor: 42.937

Review 4.  Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Andrea L Jorgensen; Ruwanthi Kolamunnage-Dona
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

5.  Fighting for recovery on multiple fronts: The past, present, and future of clinical trials for spinal cord injury.

Authors:  Valerie A Dietz; Nolan Roberts; Katelyn Knox; Sherilynne Moore; Michael Pitonak; Chris Barr; Jesus Centeno; Scott Leininger; Kent C New; Peter Nowell; Matthew Rodreick; Cedric G Geoffroy; Argyrios Stampas; Jennifer N Dulin
Journal:  Front Cell Neurosci       Date:  2022-09-07       Impact factor: 6.147

6.  A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints.

Authors:  Cornelia Ursula Kunz; Tim Friede; Nicholas Parsons; Susan Todd; Nigel Stallard
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.